US › Healthcare

Tela Bio Inc (TELA)

US · Healthcare · Medical Devices

$0.97-3.47%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$19.3M

Revenue YoY

-4.5%

Net profit

$-11.3M

EPS

$-0.20

EPS estimate

$-0.17

Net margin

-58.4%

EPS came in at -0.20 against a street estimate of -0.17 — a miss of 17.6%.

Key statistics

Market cap

$48.8M

Forward P/E

0.0

P/B

7.30

Book value

$-0.35

EPS (TTM)

$-0.77

52-week high

$1.56

52-week low

$0.50

50-day MA

$0.94

200-day MA

$0.86

Beta

1.36

Analyst view

Analysts rate Tela Bio Inc a strong buy (5 buy, 1 hold, 0 sell out of 6) with an average price target of $2.08.

Shareholding

Insiders

7.11%

Institutions

63.29%

Largest institutional holders

Fund	Stake
Nantahala Capital Management, LLC	26.11%
Essex Woodlands Health Ventures	17.09%
Stonepine Capital Management Llc	5.90%
SILVERARC CAPITAL MANAGEMENT, LLC	4.73%
Vanguard Capital Management, LLC	3.47%
Dafna Capital Management LLC	3.19%
Perkins Capital Management Inc	3.05%
Sio Capital Management, LLC	1.41%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Tela Bio Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.